Skip to main content
. 2013 May 31;5(5):801–809. doi: 10.4161/mabs.25215

Table 3. Pharmacokinetics and HACA response of ch14.18/CHO treated neuroblastoma patients.

Patient
ID		 Course Dosage
(mg/m2/d)		 Tmax
(h)		 Cmax
(μg/ml)		 T 1/2
(h)		 AUC
(μg/ml*h)		 V dis HACA* OD†
(450nm)
 
1
 1
 10
 104.0
 10.7
 50.0
 1483.4
 2.5
 -
 < 0.1
 
 2
 10
 106.0
 7.6
 1.3
 362.4
 0.2
 +
 0.46
 
 3
 10
 n.a.
 n.a.
 n.a.
 n.a.
 n.a.
 +
 1.61
2
 1
 10
 104.5
 9.6
 5.1
 360.9
 0.9
 -
 < 0.1
 
 2
 10
 104.0
 2.5
 208.5
 91.8
 121
 -
 < 0.1
3
 1
 10
 105.0
 9.5
 45.6
 1236.6
 2.8
 +
 0.26
 
 2
 10
 104.5
 9.0
 10.1
 350.1
 2.6
 +
 1.51
4
 1
 20
 112.0
 26.6
 n.a.
 1874.8
 n.a.
 -
 < 0.1
5
 1
 20
 104.0
 16.9
 121.7
 4242.2
 4.0
 -
 < 0.1
 
 2
 20
 10.0
 23.0
 140.1
 6600.1
 2.9
 -
 < 0.1
6
 1
 20
 108.0
 15.0
 102.5
 2979.9
 4.8
 -
 < 0.1
 
 2
 20
 104.0
 19.7
 55.6
 2698.5
 2.9
 -
 < 0.1
7
 1
 20
 106.0
 13.6
 196.5
 2579.2
 9.6
 -
 < 0.1
 
 2
 20
 104.5
 14.2
 203.6
 1998.5
 9.0
 -
 < 0.1
 
 3
 20
 104.0
 12.9
 51.6
 1399.4
 5.3
 -
 < 0.1
8
 1
 20
 10.0
 7.4
 75.5
 1287.1
 8.3
 -
 < 0.1
 
 2
 20
 104.0
 14.4
 38.1
 1628.6
 3.6
 -
 < 0.1
9
 1
 20
 8.5
 21.3
 40.0
 2145.7
 2.3
 -
 < 0.1
 
 2
 20
 104.0
 12.8
 23.7
 1163.0
 2.7
 -
 < 0.1
10
 1
 20
 104.5
 19.8
 25.6
 1972.2
 2.3
 -
 < 0.1
 
 2
 20
 104.0
 9.7
 4.9
 182.7
 5.8
 +
 0.14
 
 3
 20
 104.0
 9.7
 4.5
 259.8
 3.4
 +
 1.28
11
 1
 20
 96.5
 11.6
 135.7
 4293.3
 4.2
 -
 < 0.1
 
 2
 20
 104.0
 5.6
 n.a.
 46.5
 n.a.
 -
 < 0.1
12
 1
 30
 105.0
 17.0
 33.0
 1302.2
 3.6
 -
 < 0.1
 
 2
 30
 104.0
 18.3
 18.6
 1356.0
 2.3
 -
 < 0.1
 
 3
 30
 104.0
 6.3
 119.8
 2163.9
 11.7
 -
 < 0.1
13
 1
 30
 106.0
 22.8
 66.1
 3375.3
 4.2
 -
 < 0.1
 
 2
 30
 104.5
 17.0
 27.7
 1623.1
 3.7
 -
 < 0.1
 
 3
 30
 104.0
 27.9
 19.7
 5801
 3.1
 -
 < 0.1
14
 1
 30
 104.0
 27.4
 30.1
 3527.9
 1.9
 -
 < 0.1
 
 2
 30
 104.0
 24.4
 21.6
 2260.4
 2.2
 -
 < 0.1
  3 30 106.0 22.6 24.3 1772.7 2.7 - < 0.1

Legend: * positive (+) human anti-chimeric response corresponds with an OD 450 reading of > 0.1. † OD 450 values were given in HACA positive patients in subsequent courses. n.a. not available.